FDA Warning Letter: Advance-Esthetic LLC (Devices)
FDA says Zemits CrystalFrax Pro, Abigon Pro and Bionexis Lite Pro RF and light body-contouring devices lack required FDA approval or clearance.
What changed & why it matters
MedSpaRadar recorded an FDA Warning Letter at the federal level, dated August 25, 2026, in the Aesthetic Devices category.
An FDA Warning Letter is a formal, public notice that a firm's conduct violated federal law. For a med spa it is a supplier-and-marketing signal: it names conduct the FDA considers unlawful, from compounding practices to the health claims a practice might echo.
- Type
- FDA Warning Letter
- Jurisdiction
- Federal
- Category
- Aesthetic Devices
- Recorded
- August 25, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
Firm inspection: Voluntary Action Indicated
This firm’s most recent FDA inspection was classified Voluntary Action Indicated (VAI) — objectionable conditions FDA expects the firm to correct.
Source: FDA Data Dashboard inspection classifications (most recent, by firm FEI).
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
FDA Warning Letter · primary source ↗
Related alerts
- FDA device recall (Class II): Product Name: DermaV Laser System Model/Catalog Number: DermaV Medical laser device that delivers pulsed laser energy a…
- FDA device recall (Class II): Clarity II Laser System; Model No. 1110200210.
- FDA device recall (Class II): Brand Name: Leaseir Product Name: Leaseir Mhr Xcell Model/Catalog Number: Mhr 110-b Software Version: 1.5.0.0 Product D…
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.